NDA 017863 · Baxter Hlthcare
Sorbitol 3% In Plastic Container
Sorbitol · Irrigation
Last checked: Nov 20, 2026Latest source record: Mar 23, 2004 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1980
May 30, 1980
Approved uses
1
Original approval plus efficacy supplements
Registered trials
150
46 Phase 3, 17 recruiting
FAERS reports
603
517 serious, 118 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Dec 31, 2019.
INDICATIONS AND USAGE 3% Sorbitol Urologic Irrigating Solution is indicated for use as a urologic irrigating fluid with endoscopic instruments during transurethral procedures requiring distension, irrigation, and lavage of the urinary bladder. It may be used for lavage of an indwelling catheter to maintain patency.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- May 30, 1980 Original approval · Type 5 - New Formulation or New Manufacturer
1 products under this application
- SORBITOL 3% IN PLASTIC CONTAINER · SORBITOL 3GM/100ML · SOLUTION, IRRIGATION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Sorbitol" as an intervention, any sponsor and status, largest first.
- Xylitol and the Prevention of Periodontal Disease and Preterm Birth TrialPivotal-lookingRecruiting
University of WashingtonAcademic, hospital or other
NCT07424846 · 6,000 participants (planned) · Start Mar 26, 2026 · Primary completion Sep 30, 2030
Drug: Xylitol Chewing gum · For: Preterm Birth; Low Birthweight Neonate; Periodontitis and 2 more
Sites: Lilongwe, Malawi
- Rectal Indomethacin Versus Rectal Indomethacin and Sublingual Nitrate for PEP PreventionPivotal-lookingStatus unknown
Air Force Military Medical University, ChinaAcademic, hospital or other
NCT04425993 · 2,700 participants · Start Jul 1, 2020 · Primary completion May 30, 2022
Drug: Isosorbide Dinitrate 5 MG; Indomethacin 100 MG and 2 more · For: Post-ERCP Acute Pancreatitis
Sites: Xiamen, China; Lanzhou, China; Xi'an, China · 4 sites in all
- A Study of SII Yellow Fever Vaccine to Compare Safety and Immunogenicity With STAMARIL® In Healthy InfantsPivotal-lookingStatus unknown
Serum Institute of India Pvt. Ltd.Industry
NCT05447377 · 2,216 participants (planned) · Start Sep 16, 2022 · Primary completion Jan 30, 2024
Drug: SII Yellow Fever Vaccine; STAMARIL® · For: Yellow Fever
Sites: Bamako, Mali; Banjul, The Gambia
- Intensive Arterial Pressure Control in Acute Coronary SyndromePivotal-lookingCompleted
University of MonastirAcademic, hospital or other
NCT02135315 · 1,500 participants · Start Mar 2014 · Primary completion Dec 31, 2020
Drug: Isosorbide Dinitrate · For: Acute Coronary Syndrome
Sites: Monastir, Tunisia
- Safety and Immunogenicity of Sequential Rotavirus Vaccine SchedulesPivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT01266850 · 1,384 participants · Start Mar 2011 · Primary completion Oct 2013
Drug: Rotarix®; RotaTeq® · For: Rotavirus Infection
Sites: Oakland, California; Atlanta, Georgia; Iowa City, Iowa · 13 sites in all
- DECONGEST-AHF: Vasodilatation or Loop Diuretics in Acute Heart FailurePivotal-lookingRecruiting
Copenhagen University Hospital, RigshospitaletAcademic, hospital or other
NCT05276219 · 1,041 participants (planned) · Start Sep 14, 2023 · Primary completion May 1, 2027
Drug: Furosemide Injection; Isosorbide Dinitrate and 1 more · For: Pulmonary Edema; Congestive Heart Failure; Acute Heart Failure
Sites: Copenhagen, Denmark; Herlev, Denmark; Hillerød, Denmark · 5 sites in all
- Safety and Efficacy of AT-001 in Patients With Diabetic CardiomyopathyPivotal-lookingActive, not recruiting
Applied Therapeutics, Inc.Industry
NCT04083339 · 675 participants (planned) · Start Sep 20, 2019 · Primary completion Dec 2023
Drug: AT-001; Placebo · For: Diabetic Cardiomyopathies
Sites: Beverly Hills, California; La Jolla, California; Lincoln, California · 79 sites in all
- Bi Treatment With Hydralazine/Nitrates Versus Placebo in Africans Admitted With Acute Heart FailurePivotal-lookingStatus unknown
University of Cape TownAcademic, hospital or other
NCT01822808 · 500 participants (planned) · Start Jan 2013 · Primary completion Jan 2016
Drug: Hydralazine; Isosorbide Dinitrate · For: Acute Heart Failure; Left Ventricular Dysfunction
Sites: Cape Town, South Africa
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- vomiting44
- nausea43
- diarrhoea41
- constipation38
- acute kidney injury36
- fatigue36
- pain36
- asthenia32
- chronic kidney disease32
- fall32
- renal failure29
- hypotension28
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 43 |
| 2006 | 12 |
| 2007 | 13 |
| 2008 | 15 |
| 2009 | 27 |
| 2010 | 20 |
| 2011 | 17 |
| 2012 | 17 |
| 2013 | 28 |
| 2014 | 30 |
| 2015 | 27 |
| 2016 | 36 |
| 2017 | 31 |
| 2018 | 47 |
| 2019 | 38 |
| 2020 | 34 |
| 2021 | 41 |
| 2022 | 20 |
| 2023 | 19 |
| 2024 | 21 |
| 2025 | 16 |
| 2026 | 19 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Systematic review and updated meta-analysis of the use of drug-coated balloon angioplasty versus plain old balloon angioplasty for femoropopliteal arterial disease.
Caradu C, Lakhlifi E, Colacchio EC, et al. · J Vasc Surg 2019 · Meta-Analysis, Systematic Review
- Effects of Xylitol-laced Sweets on the Accumulation of Dental Plaque : A Systematic Review and Meta-Analysis.
Mostafazadehbakhtiyary M, Majidinia S, Sohouli M, et al. · Int Dent J 2025 · Systematic Review, Meta-Analysis
- Antiplaque and antigingivitis efficacy of medicated and non-medicated sugar-free chewing gum as adjuncts to toothbrushing: systematic review and network meta-analysis.
Muniz FWMG, Zanatta FB, Muñoz MDS, et al. · Clin Oral Investig 2022 · Network Meta-Analysis, Systematic Review
- The impact of polyol-containing chewing gums on dental caries: a systematic review of original randomized controlled trials and observational studies.
Deshpande A, Jadad AR · J Am Dent Assoc 2008 · Systematic Review
- Clinical Effects of Sugar Substitutes on Cariogenic Bacteria: A Systematic Review and Meta-Analysis.
Liang NL, Luo BW, Sun IG, et al. · Int Dent J 2024 · Systematic Review, Meta-Analysis
- Effect of single-administration of D-sorbitol pretreatment on the bitterness and continued willingness to take asenapine: a randomized, single-blind, placebo-controlled, crossover trial.
Wada S, Iwamoto K, Okumura H, et al. · BMC Psychiatry 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Baxter Hlthcare
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.